Drugs / S-1226
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02616770 | Mar → May 2014 | asthma | SolAeroMed Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03903913 | Aug 2019 → Feb 2022 | bronchiectasis, cystic fibrosis | SolAeroMed Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-1226 | “S-1226 is a novel drug being developed for the treatment of acute asthma exacerbations.” PMID 27464582 ↗ Jul 2016 |
| Modality | Other / unclassified | “novel biophysical bronchodilator” PMID 27464582 ↗ Jul 2016 |
| Route | Inhaled | “S-1226 administered by nebulization” NCT02616770 ↗ |